Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596184 | 0.85 | CYP3A4 (0.50) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL3839260 | 0.79 | CYP3A4 (0.47) | CYP3A4ACHEALDH1A1MAPTNOTUM | |
| SCHEMBL10596884 | 0.79 | KDM4E (0.47) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL21783817 | 0.79 | CYP3A4 (0.45) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL25329987 | 0.78 | CYP3A4 (0.64) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL22532419 | 0.77 | PTPN1 (0.35) | ALDH1A1MAPK1SMN1; SMN2MAPTRXFP1 | |
| SCHEMBL1868008 | 0.76 | ALDH1A1 (0.48) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL1727042 | 0.76 | CYP3A4 (0.42) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL22060772 | 0.76 | CYP3A4 (0.42) | CYP3A4ACHEALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL31392335 | 0.76 | AKR1C3 (0.38) | ALDH1A1MAPK1SMN1; SMN2DHODHTPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3952870-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO LTD (CN) | 2025-09-24 | — | — | EP | disclosed |
| US-20240408088-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-12-12 | — | — | US | disclosed |
| CN-114258393-B | Heterocyclic compounds having dual inhibitory activity of phosphatidylinositol 3-kinase delta and gamma and medical uses thereof | 中国医药研究开发中心有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4442680-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Abbisko Therapeutics Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| CN-117730075-A | Pyrazole derivative, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4291235-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117120090-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2020210379-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | HANGZHOU ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | WO | disclosed |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-10112955-B2 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3368530-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | Effector Therapeutics Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-2108642-A1 | JAK INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408088-A1 | PYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | PRMT5, PRMT1, PRMT8 | CYP3A4 125/4885ACHE 2043/4885ALDH1A1 3287/4885 |
| US-10112955-B2 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | NEK9, NEK2, NEK3 | CYP3A4 2201/4885ACHE 2044/4885ALDH1A1 2954/4885 |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | CYP3A4 2201/4885ACHE 2044/4885ALDH1A1 2954/4885 |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | CYP3A4 2201/4885ACHE 2044/4885ALDH1A1 2954/4885 |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | CYP3A4 3701/4885ACHE 4765/4885ALDH1A1 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.